je.st
news
Home
› Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments
Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments
2014-03-05 05:29:31| drugdiscoveryonline News Articles
Eisai Co., Ltd. and Biogen Idec recently announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401
Tags: enter
develop
disease
collaboration
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||